Skip to main content
Premium Trial:

Request an Annual Quote

Matritech Launches New Website; Promotes Sales of FDA-Approved Bladder Cancer Products

NEW YORK, Aug. 13 (GenomeWeb News)- Matritech, a developer of protein-based diagnostics products for early detection of cancer, announced today that it has launched its new website at www.matritech.com

 

Designed by Boston-based Weymouth Design, Matritech's new website provides updated information on the company's products that are in development and on the market, and allows physicians to order Matritech's NMP22 BladderChek Test online.

 

Matritech's first two products, the NMP22 BladderChek test and NMP22 test kit have been approved by the US Food and Drug Administration for the monitoring and diagnosis of bladder cancer. Aside from developing products for bladder cancer, the company has also used its proteomics technology to discover proteins associated with cervical, prostate, breast and colon cancer.

 

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.